Chineo Therapeutics Appoints Professor Gao Bin as Chief Scientific Officer to Advance Innovative TIL-Based Cancer Immunotherapies

On February 18, 2021, Beijing Cartey Therapeutics, a representative company in China for innovative cell therapy technologies such as TIL and neoantigen therapies, announced the appointment of Professor Gao Bin as its Chief Scientific Officer (CSO).

Professor Gao Bin studied under Professor Alain Townsend of the University of Oxford, a pioneer in T-cell specific recognition. He has devoted many years to researching the mechanisms of T-cell antigen presentation and T-cell recognition, and is committed to the engineering of immune cells, achieving profound expertise and significant accomplishments in this field. Professor Gao previously held a tenured position at University College London (UCL), served as Chief Scientist at Adaptimmune, a leading global company in the TCR-T field, and was selected for the Chinese Academy of Sciences’ “Hundred Talents Program.” He is also a Professor at the University of the Chinese Academy of Sciences, a Visiting Professor at the University of Tokyo, and served as Chief Scientist for major national research initiatives, including the National Basic Research Program (973 Program), the Ministry of Science and Technology’s overseas collaboration projects, and key special projects under the 11th Five-Year Plan.

Professor Gao Bin’s joining will advance the process development and cutting-edge exploration of Beijing Cartey Therapeutics’ innovative immuno-oncology products.

Chineo Medical is a representative enterprise in China for innovative immune cell therapies such as TIL and neoantigen-based treatments, and has undertaken multiple national- and provincial/ministerial-level research projects. The company’s “Supercharged TIL” therapy technology is dedicated to overcoming solid tumors, theoretically breaking through many limitations of traditional CAR-T, TCR-T, and TIL therapies, and offering advantages in safety, efficacy, target patient population, manufacturing turnaround time, and cost. Clinical trials of the company’s “Supercharged TIL” product for the treatment of advanced solid tumors, led by prominent principal investigators including Professor Li Jin from Shanghai East Hospital, are currently underway.